



## Programme

<b>Monday 28 September</b> <b>Covid Immunology and Vaccine Platforms</b>	
07:30 EST 12:30 BST 13:30 CET	Welcome and Introduction <b>Greg Poland</b> , <i>Editor in Chief, Vaccine and Mayo Clinic, USA</i>
07:50 EST 12:50 BST 13:50 CET	<b>The State of Vaccine Confidence: Implications for a covid-19 vaccine</b> <b>Heidi Larson</b> , <i>London School of Hygiene &amp; Tropical Medicine, UK</i>
08:20 EST 13:20 BST 14:20 CET	<b>Vaccination coverage: principles, strategies, and policies</b> <b>Giovanni Rezza</b> , <i>Director of the Department of Infectious Diseases at the Istituto Superiore di Sanità, Roma, Italy</i>
08:50 EST 13:50 BST 14:50 CET	<b>COVID-19 T cell responses</b> <b>Paul Klenerman</b> , <i>University of Oxford, UK</i>
09:20 EST 14:20 BST 15:20 CET	Morning conclusions <b>Paolo Bonanni</b> , <i>University of Florence, Italy</i>

<b>Tuesday 29 September</b> <b>Covid Vaccine Development</b>	
07:45 EST 12:45 BST 13:45 CET	Introduction and recap of Monday <b>Paolo Bonanni</b> , <i>University of Florence, Italy</i>
07:50 EST 12:50 BST 13:50 CET	<b>Preclinical and clinical development of ChAdOx1 nCoV-19</b> <b>Sarah Gilbert</b> , <i>University of Oxford, UK</i>
08:20 EST 13:20 BST 14:20 CET	<b>Rapid COVID-19 Countermeasure Development Demonstrates how Generalizable Solutions for Vaccine Antigen Design Support a Prototype Pathogen Approach for Pandemic Preparedness</b> <b>Barney Graham</b> , <i>Vaccine Research Center, NIAID, USA</i>
08:50 EST 13:50 BST 14:50 CET	<b>An Ad26 Vector-Based Vaccine for SARS-CoV-2</b> <b>Dan Barouch</b> , <i>Centre for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, USA</i>
09:20 EST 14:20 BST 15:20 CET	Overview and Closing Remarks <b>Greg Poland</b> , <i>Editor in Chief, Vaccine and Mayo Clinic, USA</i>
09:30	Close of conference